EquitySectoral/ ThematicRegularGrowthVery High

Invesco India Pharma and Healthcare Fund

Q: What is the NAV of Invesco India Pharma and Healthcare Fund?

As of 26 Oct 2026, the NAV of Invesco India Pharma and Healthcare Fund is ₹9.10 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

Q: What returns has Invesco India Pharma and Healthcare Fund delivered?

Invesco India Pharma and Healthcare Fund has returned -9.09% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

Q: What is the expense ratio of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund charges an expense ratio of 5.19% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

Q: What are the top holdings of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund's largest holdings are Max Healthcare Institute Limited (9.6%), Sun Pharmaceutical Industries Limited (9.0%), Sai Life Sciences Limited (8.6%), Apollo Hospitals Enterprise Limited (8.0%) and Manipal Health Enterprises Ltd (8.0%). Holdings are disclosed monthly and change over time.

Q: How risky is Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund sits at the very high level on our estimate of SEBI's risk-o-meter scale, its trailing-3Y volatility (annualised) is 15.8% and its worst peak-to-trough fall in our sample was 11.5%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

Q: What is the benchmark of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is benchmarked against the BSE Healthcare TRI. The alpha, beta and capture figures on this page are measured against the Nifty Healthcare TRI, the closest index whose daily history we hold.

Q: Who manages Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is managed by Aditya Khemani at Invesco.

Q: When was Invesco India Pharma and Healthcare Fund launched, and what is its objective?

Invesco India Pharma and Healthcare Fund was launched on 07 Sep 2026. its stated objective is: To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved. Both are as filed in the scheme's own Scheme Summary Document.

Q: How is Invesco India Pharma and Healthcare Fund taxed?

Invesco India Pharma and Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.

Invesco Mutual Fund · Best Sectoral & Thematic Mutual Funds

NAV

₹9.10

+1.90% 1D

as of 26 Oct 2026

This is the Regular plan of Invesco India Pharma and Healthcare Fund — bought through a distributor, whose commission is paid out of its expense ratio. Income is retained in the fund, so it shows up as NAV rather than as a payout.

Compare SIP calculator

Performance

-9.09%absolute

52-week rangePrev NAV ₹8.93

Latest ₹9.10

Low ₹8.9315th percentile of its 52-week rangeHigh ₹10.09

Scorecard

Not rated

How this is computed

Each verdict is computed from this fund's own metrics against its sub-category — the number behind it is shown, not a black-box rating. Not rated — this fund has no full year of NAV history yet. A rating needs at least a 1-year return to rank its performance against peers.

Performance—

No 3-year record to rank on yet

RiskModerate

Volatility 15.8% vs 15.7% category avg

CostHigh

5.2% expense vs 2.4% category avg

Consistency—

Not enough history for a rolling 3Y view

Strengths & concerns

Generated from this fund's own numbers against its sub-category — each point names the figure behind it.

Strengths

No standout strengths identified.

Concerns

High expense ratio (5.19%) vs the Sectoral/ Thematic average of 2.44%

Key Metrics

Annual fee charged by the fund, already deducted from NAV

5.19%

Direct 3.30% · Regular 5.19%

Category 2.44%▲2.75%

Portfolio-weighted harmonic mean P/E across the fund's equity holdings

59.74

Category —

Excess return per unit of total volatility (rf = 6.5%)

—

Category 0.36

Scheme Info

Definitions

Plan

Regular · Growth

Period before units can be redeemed — 3 years for ELSS, none for most open-ended funds

None

^: For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows: • if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50% • if units are redeemed/switched-out after 3 months: Nil • Switch between the Plans under the Scheme: Nil ^Exit Load charged, if any, will be credited back to the scheme, net of Goods and Services Tax

Up to 0.50%

tiered — see the full terms

Statutory levy on every mutual-fund purchase since 1 Jul 2020 (SEBI / Govt of India) — the same for every scheme

0.005%

SIP Inv.

Allowed

Smallest recurring SIP instalment the scheme accepts

₹100

Smallest one-time (lumpsum) investment the scheme accepts

₹1,000

BSE Healthcare TRI

The scheme's allotment date, as filed in its Scheme Summary Document. This plan's NAV history may begin later — Direct plans only exist from 1 Jan 2013.

07 Sep 2026

Period returns (<1Y, absolute — not annualized)

Definitions

Absolute return over the last 1 month (not annualized)

-8.54%

Absolute return over the last 3 months (not annualized)

—

Absolute return over the last 6 months (not annualized)

—

Absolute return since 1 Jan of this year (not annualized)

—

Annualized returns (≥1Y — CAGR)

Definitions

1-year point-to-point return, annualized (CAGR)

—

3-year annualized return (CAGR)

—

5-year annualized return (CAGR)

—

10-year annualized return (CAGR)

—

Annualized return (CAGR) since the first NAV we hold for this plan — the Inception date under Key metrics. AMFI's history starts in April 2006, so an older scheme is measured from there.

-9.09%

Advanced metrics — risk and benchmark ratios

Risk (trailing 3Y)

Definitions

Annualized standard deviation of daily returns

15.81%

Excess return per unit of total volatility (rf = 6.5%)

—

Excess return per unit of downside deviation — upside swings aren't penalized (rf = 6.5%)

—

Largest peak-to-trough decline over full history

-11.50%

Benchmark ratios (vs Nifty Healthcare TRI · 36 monthly returns)

Definitions

Jensen's alpha (annualized): return above what CAPM predicts for the fund's beta vs Nifty Healthcare TRI

—

Sensitivity to Nifty Healthcare TRI moves; 1 = moves with the index

—

How much of the fund's movement Nifty Healthcare TRI explains

—

Excess return per unit of beta (market risk)

—

Active return over the benchmark per unit of tracking error

—

Annualized std dev of fund-minus-benchmark returns

—

Fund's share of benchmark gains in up months (100 = matches index)

—

Fund's share of benchmark losses in down months (lower is better)

—

Computed vs the Nifty Healthcare TRI over the last 36 complete months — the closest match to this fund's mandate. TRI means dividends reinvested, as they are in the fund's own NAV; ₹ means a US index converted at each day's USD/INR, since the fund is priced in rupees; price means no free daily yield exists for that index, so the fund's alpha includes roughly the index's dividend yield. Needs ~3 years of history; a low R² means the fund tracks the index loosely.

Fund vs category average (Sectoral/ Thematic)

Period	Fund	Category avg.	Diff
1M abs	-8.54%	-5.65%	-2.89%
3M abs	—	-4.73%	—
6M abs	—	-0.63%	—
1Y CAGR	—	-3.21%	—
3Y CAGR	—	+12.53%	—
5Y CAGR	—	+9.88%	—

Category average across peers in Sectoral/ Thematic (up to 256 funds with data), same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).

Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.

Backtest this fund

What a SIP or one-time investment would have grown to over this fund’s real NAV history.

Monthly investment (₹)

Period

Invested

₹10.00K

Current value

₹10.00K

Absolute

0.00%

XIRR

+450.01%

Value vs. invested

ValueInvested

Pick a longer period to plot the path.

1 monthly installments of ₹10,000 into Invesco India Pharma and Healthcare Fund, valued at the latest NAV. XIRR annualizes for each installment’s timing.

Recent changes

Expense-ratio, fund-manager, exit-load and minimum-investment changes we've picked up in the last 30 days.

Expense ratio up: 2.47% → 5.19%
02 Oct 2026

History points

Expense ratio

5.19%

AUM

₹110.81Cr

Portfolio turnover

Exit load

Portfolio, AUM & scheme details shown from another plan of this scheme (same underlying portfolio).

P/E ratio

59.7

P/B ratio

10.3

Avg market cap

₹1,15,583Cr

P/E & P/B are portfolio-weighted harmonic means across 12 of 13 equity holdings (79% of the portfolio); loss-making companies are excluded.

Taxation

Taxed as equity

This is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.

Short-term (STCG)

20%

Held under 1 year

Flat, on the whole gain

Long-term (LTCG)

12.5%

Held 1 year or more

On gains above ₹1.25 L per financial year

Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.

Peer comparison · Sectoral/ Thematic

Compare all


Invesco India Pharma and Healthcare FundThis fund Invesco · Regular · Growth	—	—	—	—	—	5.19%	₹110.81Cr
Nippon India Taiwan Equity Fund Nippon India · Regular · Growth	★★★★☆	+91.06%	+54.88%	—	—	2.36%	₹1,100Cr
HDFC Defence Fund HDFC · Regular · Growth	★★★★☆	+10.88%	+33.69%	—	—	1.80%	₹11,128Cr
HDFC Pharma and Healthcare Fund HDFC · Regular · Growth	★★★★★	+17.42%	+27.78%	—	—	2.13%	₹3,128Cr
Aditya Birla Sun Life International Equity Fund Aditya Birla Sun Life · Regular · Growth	★★★★☆	+14.06%	+22.97%	+10.93%	—	2.55%	₹332.57Cr
Nippon India Japan Equity Fund Nippon India · Regular · Growth	★★★☆☆	+23.91%	+22.93%	+9.14%	—	2.50%	₹347.48Cr

Market-cap allocation · AMFI bands, Jul 2026

Equity holdings by company size — 100% of the equity sleeve priced.

Large cap34.2%
Mid cap28.1%
Small cap37.7%

Asset allocation

As on 30 Sep 2026 · AMC disclosure

Equity87.01%
Cash & Equivalents12.99%

which companies this fund invests in

As on 30 Sep 2026 · AMC disclosure

Max Healthcare Institute Limited

9.58%

Sun Pharmaceutical Industries Limited

8.99%

Sai Life Sciences Limited

8.63%

Apollo Hospitals Enterprise Limited

8.03%

Manipal Health Enterprises Ltd

7.98%

Divi's Laboratories Limited

7.85%

Global Health Limited

7.00%

Dr Agarwals Health Care Limited

6.32%

Corona Remedies Limited

6.13%

Torrent Pharmaceuticals Limited

4.93%

Holds the same stocks as (by portfolio overlap, not by category)

Compare the top 3 →

Fund	Overlap	Rating	TER	3Y
Mirae Asset Healthcare Fund Mirae Asset · Sectoral/ Thematic	46.5%	★★★★★	0.62%	+22.49%
LIC MF Healthcare Fund LIC · Sectoral/ Thematic	43.6%	★★★★★	1.38%	+21.13%
PGIM India Healthcare Fund PGIM India · Sectoral/ Thematic	43.6%	★★★★★	0.98%	—
DSP Nifty Healthcare Index Fund DSP · Index Funds	43.4%	★★★★★	0.40%	—
SBI Healthcare Opportunities Fund SBI · Sectoral/ Thematic	43.0%	★★★★★	1.01%	+23.13%
ITI Pharma and Healthcare Fund ITI · Sectoral/ Thematic	41.7%	★★★★★	0.89%	+19.13%
HDFC Pharma and Healthcare Fund HDFC · Sectoral/ Thematic	41.0%	★★★★★	1.05%	+29.30%
WhiteOak Capital Pharma and Healthcare Fund WhiteOak Capital · Sectoral/ Thematic	39.5%	★★★★★	1.07%	—

Overlap is the share of each fund's equity book invested in the same stocks, by weight, across the Direct-plan universe — so a fund that is only part equity is labelled as such. ! marks a pair holding more in common than nine pairs in ten of its type, where that type has a measured distribution.

Worst falls, and the wait to get back

How far this fund has dropped from a high, and how long it took to reclaim it.

-11.5%23 Sep 2026 → 23 Oct 2026
Still below that high — 30 days down, and no recovery yet.

Measured on this fund’s own NAV history, peak to trough to the day it regained the peak. Falls shallower than 5% are left out. A recovery date is when the NAV got back, not when any particular investor did — that depends on when they bought.

AMC Profile

Invesco Mutual Fund is the Indian arm of Invesco, the US asset manager. It began life as Lotus India Mutual Fund, was bought by Religare in 2008 and ran as Religare Invesco until Invesco took full ownership in 2016.

Launched

23 Jul 2006

Total AUM

₹1,64,687Cr+12.8% QoQ

Avg AUM · July - September 2026

Website

invescomutualfund.com

Fund Managers

AKAditya KhemaniManaging since 07 Sep 2026

Role

EVP & Fund Manager - Equity

Total experience

More than 20 years

Education

B.Com., PGDM - Finance (IIM, Lucknow)

Experience

November 1, 2023 onwards Invesco Asset Management (India) Pvt. Ltd. July 24, 2019 to October 31, 2023 EVP & Fund Manager - Equity - Motilal Oswal Asset Management India Company Limited October 1, 2007 to July 23, 2019 SVP and Fund Manager - Equity - HSBC Asset Management (India) Pvt. Ltd.

Funds managed (5)

All schemes Aditya Khemani runs →

Fund managers from the AMC's filed Scheme Summary — its most recent filing for this scheme. Each manager's qualifications and role are reconciled across every filing this fund house makes for them, including its Statement of Additional Information. Total AUM via AMFI.

Explore from here

Fund managers

Aditya Khemani

Top holdings

Max Healthcare Institute Limited Sun Pharmaceutical Industries Limited Sai Life Sciences Limited Apollo Hospitals Enterprise Limited Manipal Health Enterprises Ltd Divi's Laboratories Limited Global Health Limited Dr Agarwals Health Care Limited Corona Remedies Limited Torrent Pharmaceuticals Limited Glenmark Pharmaceuticals Limited Krishna Institute Of Medical Sciences Limited

Invesco in the news

Headlines about the fund house, not this scheme in particular — highlights only; tap through to read the full story at the source.

Run SIP calculator Add to compare

Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.

About Sectoral & Thematic funds

Sectoral and thematic funds must keep at least 80% in the equity of one sector (banking, pharma, technology) or one theme (consumption, manufacturing, ESG). That concentration is the point and the risk: with no mandate to diversify away from the sector, the fund rises and falls with it.

Frequently asked questions

What is the NAV of Invesco India Pharma and Healthcare Fund?

As of 26 Oct 2026, the NAV of Invesco India Pharma and Healthcare Fund is ₹9.10 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

What returns has Invesco India Pharma and Healthcare Fund delivered?

Invesco India Pharma and Healthcare Fund has returned -9.09% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

What is the expense ratio of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund charges an expense ratio of 5.19% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

What are the top holdings of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund's largest holdings are Max Healthcare Institute Limited (9.6%), Sun Pharmaceutical Industries Limited (9.0%), Sai Life Sciences Limited (8.6%), Apollo Hospitals Enterprise Limited (8.0%) and Manipal Health Enterprises Ltd (8.0%). Holdings are disclosed monthly and change over time.

How risky is Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund sits at the very high level on our estimate of SEBI's risk-o-meter scale, its trailing-3Y volatility (annualised) is 15.8% and its worst peak-to-trough fall in our sample was 11.5%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

What is the benchmark of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is benchmarked against the BSE Healthcare TRI. The alpha, beta and capture figures on this page are measured against the Nifty Healthcare TRI, the closest index whose daily history we hold.

Who manages Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is managed by Aditya Khemani at Invesco.

When was Invesco India Pharma and Healthcare Fund launched, and what is its objective?

Invesco India Pharma and Healthcare Fund was launched on 07 Sep 2026. its stated objective is: To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved. Both are as filed in the scheme's own Scheme Summary Document.

How is Invesco India Pharma and Healthcare Fund taxed?

Invesco India Pharma and Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.